US Stock MarketDetailed Quotes

SDGR Schrodinger

Watchlist
  • 19.820
  • +0.060+0.30%
Trading Dec 24 11:55 ET
1.44BMarket Cap-8.09P/E (TTM)

About Schrodinger Company

Schrodinger, Inc. It was registered in California in August 1990 in accordance with relevant laws. The company has developed a physics-based computing platform that can predict the key properties of molecules with high accuracy, so that high-quality and new molecules for drug development and material applications can be discovered more quickly at lower cost. Their software is used by biopharmaceuticals, industrial companies, academic institutions and government laboratories around the world. The company is a leading provider of computing software solutions for drug discovery. In addition to providing customers with a variety of software solutions, the company accelerates all stages of molecular discovery, design and optimization. They also use their platforms and capabilities to cover a wide range of disease targets and indications through a series of collaborative and wholly-owned drug discovery programs.

Company Profile

SymbolSDGR
Company NameSchrodinger
Listing DateFeb 6, 2020
Issue Price17.00
Founded1990
CEODr. Ramy Farid, PhD
MarketNASDAQ
Employees867
Fiscal Year Ends12-31
Address1540 Broadway,24th floor
CityNew York
ProvinceNew York
CountryUnited States of America
Zip Code10036-4041
Phone1-212-295-5800

Company Executives

  • Name
  • Position
  • Salary
  • Dr. Ramy Farid, PhD
  • Director, Chief Executive Officer and President
  • 3.12M
  • Dr. Margaret Dugan
  • Chief Medical Officer
  • 3.15M
  • Dr. Geoffrey Porges, M.B.B.S.
  • Executive Vice President and Chief Financial Officer
  • 1.65M
  • Yvonne Tran
  • Executive Vice President, Chief Legal Officer and Corporate Secretary
  • --
  • Kenneth Patrick Lorton
  • Chief Operating Officer, Software, Executive Vice President and Chief Technology Officer
  • --
  • Jenny Herman
  • Senior Vice President, Finance, Corporate Controller and Principal Accounting Officer
  • --
  • Dr. Robert Abel, PhD
  • Executive Vice President, Chief Computational Scientist and Head of Modeling R&D
  • 1.70M
  • Dr. Karen Akinsanya, PhD
  • President, R&D Therapeutics
  • 1.68M
  • Michael M. Lynton
  • Chairman of the Board
  • 727.05K
  • Dr. Richard A. Friesner, PhD
  • Director
  • 1.09M
  • Gary L. Sender
  • Independent Director
  • 707.05K
  • Arun Oberoi
  • Independent Director
  • 682.05K
  • Gary L. Ginsberg
  • Independent Director
  • 672.05K
  • Dr. Rosana Kapeller-Libermann, M.D.,PhD
  • Independent Director
  • 687.05K
  • Dr. Jeffrey A. Chodakewitz, M.D.
  • Independent Director
  • 692.05K
  • Nancy A. Thornberry
  • Independent Director
  • 684.55K
Trending US Stocks
Fed Rate Cut Beneficiaries Fed Rate Cut Beneficiaries

Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only. This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data. Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only. This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data.